Genor Biopharma held its shareholders' annual meeting on June 18, 2024, and voted on proposals including the adoption of the audited financial statements, director elections and remuneration authorizations. All ordinary and special resolutions were approved, including the adoption of the audited financial statements, board of directors' report and auditor's report for the fiscal year 2023, as well as the re-election and remuneration authorization of directors. In addition, PwC was re-appointed as the auditor and the board of directors was authorized to issue additional shares not exceeding 20% of the total issued shares, repurchase no more than 10% of shares, and expand the general authorization for the issuance of shares. Shareholders also approved the ninth amended and restated outline and regulations of the company's articles of association. The meeting was attended electronically by six of the nine directors, including Chairman and Executive Director Dr. Li Yiping.

Genor Biopharma held its shareholders' annual meeting on June 18, 2024, and voted on proposals including the adoption of the audited financial statements, director elections and remuneration authorizations. All ordinary and special resolutions were approved, including the adoption of the audited financial statements, board of directors' report and auditor's report for the fiscal year 2023, as well as the re-election and remuneration authorization of directors. In addition, PwC was re-appointed as the auditor and the board of directors was authorized to issue additional shares not exceeding 20% of the total issued shares, repurchase no more than 10% of shares, and expand the general authorization for the issuance of shares. Shareholders also approved the ninth amended and restated outline and regulations of the company's articles of association. The meeting was attended electronically by six of the nine directors, including Chairman and Executive Director Dr. Li Yiping.